From: MedPage Today Byy: Ed Susman, Contribution Writer, MedPAge Today LAS VEGAS -- TNF inhibitors remain the predominant treatment in Crohn's disease, but ustekinumab (Stelara) has been quickly adopted by clinicians, accounting for about one in five recently switched patients, researchers reported here. The agent received FDA approval in 2016 for the treatment of moderately to severely active Crohn's disease in adults who have failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with a TNF blocker, or who failed or were intolerant to treatment with one or more TNF blockers...(read more).
From: Specialty Pharma Time By: Lauren Santye Although there are a growing number of rheumatologists in the United States who report the use of Cosentyx to treat psoriatic arthritis (PsA), the increasing user base has failed to translate into overall increases in biologic share, according to market research company Spherix Global Insights. The plateau of Cosentyx is partially fueled by pipeline PsA agents, which offer patients more options for non-TNF treatments, including Orcenia, Xeljanz, and Taltz, according to a press release....(read more).
From: The Pharma Letter Early US dermatologist's views of Tremfya leave ground to be covered At two weeks post launch, only half of the surveyed US dermatologists (n=104) were aware of Tremfya's (guselkumab) approval when aided. The drug was approved by the US Food and Drug Administration on July 13 as a treatment for moderate to severe plaque psoriasis...(read more)